资讯内容 Content

2022年ASCO乳腺癌领域重磅研究汇总
作者:廖小雁 Xiaoyan Liao 时间:2022/5/25 16:34:16    加入收藏
 关键字:乳腺癌 
编者按:2022年美国临床肿瘤学会年会(2022 ASCO)将于当地时间6月3~7日在芝加哥以线上、线下会议的形式举行。做为规模最大的综合性会议,每年ASCO上大会的报告都会引起大家的关注和讨论。本文特将本届ASCO大会上乳腺癌领域的重磅研究进行汇总,供读者学习!
 
会议环节:Plenary Session
 
Trastuzumab deruxtecan(T-DXd)versus treatment of physician’s choice(TPC)in patients(pts)with HER2-low unresectable and/or metastatic breast cancer(mBC):Results of DESTINY-Breast04,a randomized,phase 3 study.
 
Ⅲ期随机研究(DESTINY-Breast04)的结果:对比曲妥珠单抗deruxtecan(T-DXd)与医生选择治疗(TPC)在HER2低表达、不可切除和/或转移性乳腺癌(mBC)患者中的疗效
 
摘要号:LBA3
 
讲者:Shanu Modi,MD
 
会议环节:Oral Abstract Session
 
Breast Cancer—Metastatic(6月5日)
 
Trastuzumab deruxtecan(T-DXd)versus trastuzumab emtansine(T-DM1)in patients(pts)with HER2-positive(HER2+)unresectable and/or metastatic breast cancer(mBC):Safety follow-up of the randomized,phase 3 study DESTINY-Breast03.
 
DESTINY-Breast03研究随访:对比T-DXd与T-DM1在HER2+不可切除和/或转移性乳腺癌患者中的安全性
 
摘要号:1000
 
讲者:Erika P.Hamilton,MD
 
Primary results from TROPiCS-02:A randomized phase 3 study of sacituzumab govitecan(SG)versus treatment of physician’s choice(TPC)in patients(Pts)with hormone receptor–positive/HER2-negative(HR+/HER2-)advanced breast cancer.
 
Ⅲ期随机对照研究的主要结局(TROPiCS-02):在激素受体阳性/HER2阴性(HR+/HER2-)晚期乳腺癌患者(Pts)中对sacituzumab govitecan(SG)与医生选择治疗(TPC)的方案进行比较。
 
摘要号:LBA1001
 
讲者:Hope S.Rugo,MD,FASCO
 
Results from the phase 1/2 study of patritumab deruxtecan,a HER3-directed antibody-drug conjugate(ADC),in patients with HER3-expressing metastatic breast cancer(MBC)
 
HER3靶向抗体药物偶联物(patritumab deruxtecan)在HER3表达的转移性乳腺癌(MBC)患者中的1/2期研究结果。
 
摘要号:1002
 
讲者:Ian E.Krop,MD,PhD
 
Overall survival(OS)with first-line palbociclib plus letrozole(PAL+LET)versus placebo plus letrozole(PBO+LET)in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer(ER+/HER2−ABC):Analyses from PALOMA-2.
 
PALOMA-2研究分析:一线palbociclib+来曲唑(PAL+LET)与安慰剂+来曲唑(PBO+LET)治疗ER+/HER2-晚期乳腺癌患者总生存期(OS)。
 
摘要号:LBA1003
 
讲者:Richard S.Finn,MD
 
A randomized,phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition(CDK 4/6i)in patients(pts)with unresectable or hormone receptor–positive(HR+),HER2-negative metastatic breast cancer(MBC):MAINTAIN trial.
 
随机Ⅱ期试验(MAINTAIN研究):抗雌激素治疗联合CDK4/6抑制剂治疗进展后,氟维司群或依西美坦(Exemestane)联合或不联合瑞博西利(Ribociclib)用于HR+/HER2-转移性乳腺癌患者的疗效
 
摘要号:LBA1004
 
讲者:Kevin Kalinsky,MD,MS
 
Fulvestrant plus capivasertib versus fulvestrant plus placebo after relapse or progression on an aromatase inhibitor in metastatic,estrogen receptor–positive breast cancer(FAKTION):Overall survival and updated progression-free survival data with enhanced biomarker analysis.
 
氟维司群联合capivasertib对比氟维司群联合安慰剂芳香化酶抑制剂治疗进展的ER+晚期乳腺癌(FAKTION):总生存(OS)和基于生物标志物的无进展生存期(PFS)更新结果分析。
 
摘要号:1005
 
讲者:Robert Hugh Jones,PhD,FRCP
 
Alpelisib(ALP)+fulvestrant(FUL)in patients(pts)with hormone receptor–positive(HR+),human epidermal growth factor receptor 2–negative(HER2−)advanced breast cancer(ABC):Biomarker(BM)analyses by next-generation sequencing(NGS)from the SOLAR-1 study.
 
Alpelisib+氟维司群用于HR+/HER2-晚期乳腺癌(ABC)患者:在SOLAR-1研究中通过二代测序(NGS)进行的生物标志物分析。
 
摘要号:1006
 
讲者:Dejan Juric,MD
 
NRG-BR002:A phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy(SBRT)and/or surgical resection(SR)for newly oligometastatic breast cancer(NCT02364557).
 
NRG-BR002研究:新发寡转移性乳腺癌(NCT02364557)标准系统治疗伴或不伴立体定向全身放疗(SBRT)和/或手术切除(SR)的IIR/III期试验(NCT02364557)。
 
摘要号:1007
 
讲者:Steven J.Chmura,MD,PhD
 
Contributions of screening,early-stage treatment,and metastatic treatment to breast cancer mortality reduction by molecular subtype in U.S.women,2000-2017.
 
2000-2017年,筛查、早期治疗和转移性乳腺癌的治疗对降低美国女性各亚型乳腺癌死亡率的贡献。
 
摘要号:1008
 
讲者:Jennifer Lee Caswell-Jin,MD,BA
 
Breast Cancer—Local/Regional/Adjuvant(6月7日)
 
LUMINA:A prospective trial omitting radiotherapy(RT)following breast conserving surgery(BCS)in T1N0 luminal A breast cancer(BC).
 
LUMINA研究:T1N0 luminal A型乳腺癌保乳手术后省略放疗(RT)的前瞻性研究。
 
摘要号:LBA501
 
讲者:Timothy Joseph Whelan,FASCO
 
Assessing the benefit of adjuvant endocrine therapy in patients following breast-conserving surgery with or without radiation stratified by a 7-gene predictive DCIS biosignature.
 
根据7基因预测的DCIS生物标记物分层,评估保乳手术后伴或不伴放疗患者辅助内分泌治疗的获益情况。
 
摘要号:502
 
讲者:Pat W.Whitworth,MD
 
Event-free survival by residual cancer burden after neoadjuvant pembrolizumab+chemotherapy versus placebo+chemotherapy for early TNBC:Exploratory analysis from KEYNOTE-522.
 
KEYNOTE-522研究探索性分析:早期TNBC患者新辅助帕博利珠单抗+化疗对比安慰剂+化疗后残余肿瘤负担的无事件生存。
 
摘要号:503
 
讲者:Lajos Pusztai,D.Phil,MD
 
Pathologic complete response(pCR)rates for HR+/HER2-breast cancer by molecular subtype in the I-SPY2 Trial.
 
I-SPY2研究中,HR+/HER2-乳腺癌的病理完全缓解(pCR)率
 
讲者:Laura Ann Huppert,MD
 
摘要号:504
 
Measurement of endocrine activity(SET2,3)related to prognosis and prediction of benefit from dose-dense(DD)chemotherapy in estrogen receptor-positive(ER+)cancer:CALGB 9741(Alliance).
 
ER+乳腺癌患者中与预后相关的内分泌活性(SET2,3)测量和剂量密度(DD)化疗获益的预测:CALGB 9741(Alliance)。
 
摘要号:505
 
讲者:Otto Metzger,MD
 
Final results from a phase III randomized clinical trial of adjuvant endocrine therapy±chemotherapy in women≥70 years old with ER+HER2-breast cancer and a high genomic grade index:The Unicancer ASTER 70s trial.
 
Unicancer ASTER 70试验的最终结果:辅助内分泌治疗±化疗用于70岁以上ER+/HER2-乳腺癌和高基因组分级指数的女性的Ⅲ期随机临床试验。
 
摘要号:500
 
讲者:Etienne Brain,MD,PhD
 
Adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy:8-year follow-up of the randomized ASTRRA trial.
 
ASTRRA研究8年随访结果:在绝经前或化疗后恢复月经的内分泌敏感型年轻乳腺癌女性中加入他莫昔芬抑制卵巢功能。
 
摘要号:506
 
讲者:Soo Yeon Baek,MD
 
Long-term outcomes of adjuvant denosumab in breast cancer:Fracture reduction and survival results from 3,425 patients in the randomised,double-blind,placebo-controlled ABCSG-18 trial.
 
Denosumab辅助治疗乳腺癌的长期结果:在随机、双盲、安慰剂对照的ABCSG-18试验中,3425名患者的骨折复位和生存结果。
 
摘要号:507
 
讲者:Michael Gnant,MD,FACS
 
Historical early treatment effects of adjuvant endocrine therapy for breast cancer in high-risk subgroups:Reanalysis of BIG 1-98,SOFT and TEXT.
 
乳腺癌高危亚组辅助内分泌治疗的早期治疗效果:BIG 1-98、SOFT和TEXT研究再分析。
 
摘要号:508
 
讲者:Meredith M.Regan,FASCO,ScD

点击排行 Top Hits

 
关于本站 | 设为首页 | 加入收藏 | 站长邮箱 | 友情链接 | 版权申明

肿瘤瞭望 版权所有  2014-2019 ioncol.com  All Rights Reserved